Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Biologics

Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis

Lara C. Pullen, PhD  |  January 24, 2013

A new study confirms that the use of immunosuppressive drugs is associated with a reduced risk of vision loss in patients with juvenile idiopathic arthritis-related uveitis.

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:JIAJuvenile idiopathic arthritisUveitis

ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront

Mary Beth Nierengarten  |  January 1, 2013

Studies addressing rheumatoid arthritis (RA) flares, a potential new drug for psoriatic arthritis, and a novel agent in the treatment of active RA are among the highlights

Filed under:ConditionsMeeting ReportsPsoriatic ArthritisRheumatoid Arthritis Tagged with:ACR/ARHP Annual MeetingPsoriatic ArthritisRA flaresRheumatoid arthritis

The ACR Helps Members Meet Insurance Challenges

Audrey B. Uknis, MD  |  January 1, 2013

The Affiliate Society Council (ASC) and Insurance Subcommittee (ISC) support rheumatologists at a local level, while serving as a national voice for members

Filed under:President's Perspective Tagged with:AC&Rrheumatology

ACR/ARHP Annual Meeting 2012: Identify Compliance Risks to Avoid Violating Medicare Rules

Mary Beth Nierengarten  |  January 1, 2013

Rheumatologists should develop a plan to keep in step with federal regulations

Filed under:Legislation & Advocacy Tagged with:ACR/ARHP Annual MeetingMedicareRegulation

CORRONA Team Provides Data-Based Tool to Address Rheumatology’s Questions

Gretchen Henkel  |  December 1, 2012

The Consortium of Rheumatology Researchers of North America (CORRONA) patient registry collects a host of treatment and disease indicators for a variety of rheumatic diseases at every physician visit

Filed under:ConditionsGout and Crystalline ArthritisInformation TechnologyPractice SupportProfilesPsoriatic ArthritisQuality Assurance/ImprovementResearch RheumRheumatoid ArthritisTechnologyTechnology Tagged with:Goutpatient carepatient registryProfilePsoriatic ArthritisResearchRheumatoid arthritisrheumatologistTechnologyTreatment

Rheumatology Drug Updates: Apremilast, Golimumab, and More

Michele B. Kaufman, PharmD, BCGP  |  November 1, 2012

Information on new approvals and medication safety rheumatologists need to know

Filed under:AnalgesicsAxial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Ankylosing SpondylitisBiologicsBiosimilarsdrugFDAinfliximabJAK inhibitorsjanus kinaseMethotrexatePipelinePolymyalgia RheumaticaprednisonePsoriatic ArthritisRheumatoid arthritisSafetyTofacitinib

EULAR 2012: Rewards in Risk Factor Research

Thomas R. Collins  |  September 5, 2012

Investigations of infection and comorbidities offers hints to better understanding of rheumatoid arthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:EULARInfectionInternationalPainpatient careResearchRheumatoid arthritisrheumatologist

EULAR 2012: Partnership Between Physician and Patient

Thomas R. Collins  |  September 5, 2012

Patient involvement a valuable tool, especially in less common rheumatic disorders.

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting ReportsPractice SupportQuality Assurance/ImprovementSystemic Lupus ErythematosusSystemic Sclerosis Tagged with:Ankylosing SpondylitisEULARInternationalLupuspatient carepatient communicationPractice ManagementrheumatologistScleroderma

Drug Updates: Lorcaserin, Acetaminophen, and More

Michele B. Kaufman, PharmD, BCGP  |  September 5, 2012

information on new approvals and medication safety

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesPsoriatic ArthritisRheumatoid Arthritis Tagged with:acetaminophenAnkylosing SpondylitisApprovalsBiologicsdrugFDAPipelinePsoriatic ArthritisrituximabSafetySteroids

EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

Thomas R. Collins  |  August 8, 2012

Advances in the rheumatology clinic are promising, two experts say.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:BiologicsEULARHYDROXYCHLOROQUINEinfliximabInternationalMethotrexatepatient careRheumatoid arthritisrheumatologisttocilizumab

  • « Previous Page
  • 1
  • …
  • 65
  • 66
  • 67
  • 68
  • 69
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences